Sputnik V COVID-19 vaccine demonstrates 91.6% efficacy
The Lancet has published interim results of a Phase III clinical trial of Sputnik V, confirming the vaccine demonstrated efficacy of 91.6%. Sputnik V,...
Positive CHMP opinion for Novartis’ Kesimpta (ofatumumab)
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing...
EU authorisation for AstraZeneca’s COVID-19 vaccine
AstraZeneca’s COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 in individuals...
Additional 4 million doses of Valneva COVID-19 vaccine for UK
Valneva, a specialty vaccine company focused on prevention against diseases with major unmet needs, has reported that the UK Government has ordered 40 million...
Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK trial
Novavax has announced that its protein-based COVID-19 vaccine candidate has an efficacy of 89.3%, following results from its Phase III clinical trial conducted in...
Almirall and Happify Health psoriasis digital platform solution
Almirall and Happify Health have entered into a strategic partnership to develop a version of its digital platform specifically for people with psoriasis in...
NICE recommendation for REVLIMID®▼ (lenalidomide)
The National Institute for Excellence (NICE) has issued a Final Appraisal Document (FAD) recommending REVLIMID®▼ (lenalidomide) as maintenance treatment after an autologous stem cell...
UK COVID-19 death rate reaches 100,000
Latest figures from the Office for National Statistics (ONS) shows the total number of deaths in the UK involving COVID-19 is now more than...
Nearly one-third of cervical cancer Phase III clinical trials expected to conclude in 2021
Data and analytics company GlobalData has revealed that out of the 107 ongoing clinical trials worldwide for cervical cancer, 30% are estimated to be...
MSD discontinues development of its COVID-19 vaccines
MSD has announced that the company is discontinuing development of its two COVID-19 vaccine candidates, V590 and V591, following a review of findings from...
Latest articles
Reducing time to market for new COVID-19 vaccines
With the target set to offer a COVID-19 vaccine to a further 17.7 million people in the next five priority groups - including all...
NHS gives women Human Papillomavirus Virus (HPV) home testing kits
NHS England has announced that more than 31,000 women will be offered kits to carry out HPV self-sampling in the privacy and convenience of...
Tribunal upholds CMA decision on pharma collusion and £1.2m fine
The Competition Appeal Tribunal has upheld the Competition and Markets Authority (CMA)’s finding that pharmaceutical firm Lexon broke competition law, dismissing Lexon’s appeal. Last year,...
Popular articles
Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
NHS prescription charge to increase from 1 April 2021
The NHS prescription charge will increase to £9.35 per prescription item from 1 April 2021 in England, according to the Pharmaceutical Services Negotiating Committee...
NHS gives women Human Papillomavirus Virus (HPV) home testing kits
NHS England has announced that more than 31,000 women will be offered kits to carry out HPV self-sampling in the privacy and convenience of...
Tribunal upholds CMA decision on pharma collusion and £1.2m fine
The Competition Appeal Tribunal has upheld the Competition and Markets Authority (CMA)’s finding that pharmaceutical firm Lexon broke competition law, dismissing Lexon’s appeal. Last year,...